104113-97-5

Upstream product

• 72912-40-4 (2-bromo-3,4-dimethoxyphenyl)ethylamine 
• 13305-14-1 methyl 2-hydroxy-2-(4-methoxyphenyl)acetate 
• 104421-98-9 N-<2-hydroxy-2-(4-methoxyphenyl)ethyl>-2-(2-bromo-3,4-dimethoxyphenyl)acetamide 
• 621-59-0 isovanillin 
• 55171-60-3 2-bromo-3,4-dimethoxybenzylaldehyde 
• 72912-39-1 (2-bromo-3,4-dimethoxyphenyl)acetonitrile 
• 2973-58-2 2-bromoisovanillin 
• 72912-38-0 (2-bromo-3,4-dimethoxyphenyl)methanol 
• 33646-40-1 4-methoxymandelonitrile 
• 63856-83-7 2-bromo-3,4-dimethoxyphenylacetic acid 
• 104421-97-8 2-bromo-3,4-dimethoxyphenylacetyl chloride 
• 55275-61-1 2-amino-1-(4-methoxyphenyl)ethanol 
• 7477-50-1 2-bromo-1-chloromethyl-3,4-dimethoxy-benzene 

Downstream Products

• 71157-96-5 6-bromo-7,8-dimethoxy-1-(p-methoxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine 
• 67287-79-0 6-bromo-7,8-dihydroxy-1-(p-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide 
• 104421-89-8 3-Allyl-6-bromo-7,8-dimethoxy-1-(4-methoxy-phenyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine 
• 104421-90-1 3-allyl-6-bromo-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol 

Relevant academic research and scientific papers

Dopamine Agonists Related to 3-Allyl-6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol. 6-Position Modifications

The N-allyl derivative (SK and F 85174) of 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol (SK and F 82526) retains the DA-1 agonist potency of the latter compound but unlike the parent also shows substantial DA-2 agonist activity.In a previous study of N-substituted benzazepines these combined agonist effects were shown to be uniquely associated with the N-allyl group.A continuation of this research has examined dependency of combined DA-2/DA-1 agonist activities on 6=position modification with the specific objective of developing an agonist with maximum effectiveness and potency at the DA-2 receptor subtype.DA-2 agonist activity was measured in a rabbit ear artery assay, and DA-1 agonist activity was determined in an adenylate cyclase assay.Replacing chloro with bromo retains the activity pattern and the potency of the chloro compound: replacement with a hydrogen causes a decrease of both DA-1 and DA-2 receptor activating potency.Introduction of a 6-methyl group causes loss of DA-2 agonist activity and reduction in DA-1 agonist potency.Substitution with a 6-fluoro provides the best balance of DA-2 and DA-1 agonist activities; this compound was moderately in both assays.